Two Sigma Advisers LP Has $8.78 Million Holdings in Qiagen (NYSE:QGEN)

Two Sigma Advisers LP grew its holdings in shares of Qiagen (NYSE:QGEN - Free Report) by 30.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 197,112 shares of the company's stock after buying an additional 45,505 shares during the period. Two Sigma Advisers LP owned 0.09% of Qiagen worth $8,777,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the business. Groupama Asset Managment raised its holdings in shares of Qiagen by 8,074.0% during the fourth quarter. Groupama Asset Managment now owns 31,817,740 shares of the company's stock valued at $1,416,844,000 after buying an additional 32,216,761 shares during the last quarter. Massachusetts Financial Services Co. MA raised its holdings in shares of Qiagen by 9.5% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 25,319,332 shares of the company's stock valued at $1,127,470,000 after buying an additional 2,202,040 shares during the last quarter. Wellington Management Group LLP raised its holdings in shares of Qiagen by 2.5% during the fourth quarter. Wellington Management Group LLP now owns 21,782,305 shares of the company's stock valued at $970,534,000 after buying an additional 531,362 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Qiagen by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 8,879,089 shares of the company's stock valued at $397,937,000 after buying an additional 77,119 shares during the last quarter. Finally, Norges Bank bought a new stake in shares of Qiagen during the fourth quarter valued at approximately $181,529,000. Institutional investors own 70.00% of the company's stock.

Qiagen Price Performance

Qiagen stock traded up $0.40 during mid-day trading on Thursday, hitting $44.78. The company's stock had a trading volume of 320,938 shares, compared to its average volume of 1,154,642. The company has a quick ratio of 3.09, a current ratio of 3.61 and a debt-to-equity ratio of 0.38. The stock has a market capitalization of $9.95 billion, a P/E ratio of 125.00, a P/E/G ratio of 2.39 and a beta of 0.67. Qiagen has a twelve month low of $37.63 and a twelve month high of $49.30. The stock's fifty day moving average price is $41.49 and its two-hundred day moving average price is $41.84.

Qiagen (NYSE:QGEN - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.50 by $0.05. The firm had revenue of $483.46 million for the quarter, compared to analyst estimates of $465.66 million. Qiagen had a net margin of 4.23% and a return on equity of 13.92%. The firm's quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.44 earnings per share. Research analysts forecast that Qiagen will post 2.26 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages recently commented on QGEN. Redburn Atlantic cut Qiagen from a "buy" rating to a "neutral" rating in a report on Friday, April 4th. Wall Street Zen raised Qiagen from a "buy" rating to a "strong-buy" rating in a report on Thursday, May 15th. UBS Group dropped their target price on Qiagen from $50.00 to $48.00 and set a "neutral" rating on the stock in a report on Friday, February 7th. Baird R W cut Qiagen from a "strong-buy" rating to a "hold" rating in a report on Wednesday, February 19th. Finally, Robert W. Baird boosted their target price on Qiagen from $42.00 to $43.00 and gave the stock a "neutral" rating in a report on Monday, April 21st. Seven investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, Qiagen currently has an average rating of "Hold" and an average target price of $48.42.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.